Elevate Productivity and Drive Business Success

Perkins Coie Advises Xentria in Multi-Year Licensing Agreement with Meitheal to Market Xentria's Novel Biologic to Treat Pulmonary Sarcoidosis · Home ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Tom Shea is the founding President of Xentria and the founding CEO of Meitheal Pharmaceutical, Inc. Tom Shea brings experience from previous roles at Xentria, Meitheal Pharmaceuticals and Sagent Pharmaceuticals. Tom Shea holds a 2009 - 2010 Master Of Business ... 格隆汇6月27日丨健友股份(603707.SH)公布，公司全资子公司香港健友及香港健友控股子公司Meitheal拟与Xentria签署《许可协议》，Xentria授予被许可方在 ... Immunology. Study Phase : Phase I/ Phase II. Recipient : Xentria. Deal Size : $680.0 million. Deal Type : Licensing Agreement. DEALS_DEV arrow-down · Xentria ... Xentria has always been a company comfortable navigating uncertainty. Founded in 2020, we began during the early days of the COVID-19 ... Meitheal is proud to be partnered with Xentria on XTMAB-16! #xentria #XTMAB16 #pulmonarysarcoidosis. Tom is the founding CEO of Meitheal since its inception in 2017. In addition, Tom is also the founding President of Xentria, Inc. Xentria Secures Landmark Agreement with NYU for Cardiovascular Therapy Development. 12/19. iBIO - Illinois Biotechnology Industry Organization · Capital Pulse ...